Angiotensin II as a cardiovascular risk factor

Journal of Human Hypertension

Volumn 16, Issue , 2002, Pages S2-S6

  Gavras, I ^a   Gavras, H ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Angiotensin II; Cardiovascular disease; Myocardial infarction; Renin angiotensin system

Indexed keywords

ANGIOTENSIN;

ARTERY THROMBOSIS; BLOOD CLOTTING DISORDER; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CONFERENCE PAPER; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; ENERGY CONSUMPTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTENSION; MYOCARDITIS; OXIDATIVE STRESS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RISK FACTOR; SODIUM BALANCE; VASOSPASM;

ANGIOTENSIN II; ANIMALS; BLOOD FLOW VELOCITY; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; RENIN-ANGIOTENSIN SYSTEM; RISK ASSESSMENT; RISK FACTORS;

EID: 0036099831     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001392     Document Type: Article

References (68)

1. Gavras H et al. Acute renal failure, tubular necrosis and myocardial infarction induced in the rabbit by intravenous angiotensin II. Lancet 1971; 2: 19-22.
2. Gavras H et al. Angiotensin-and norepinephrine-induced myocardial lesions: experimental and clinical studies in rabbits and man. Am Heart J 1975; 89: 321-332.
3. Tan LB et al. Cardiac myocyte necrosis induced by angiotensin II. Circ Res 1991; 69: 1185-1195.
4. Weber KT, Brilla CG, Campbell SE, Reddy HK. Myocardial fibrosis and the concepts of cardioprotection and cardioreparation. J Hypertens 1992; 10 (Suppl 5): S87-S94.
5. Liang C, Gavras H, Hood WB Jr. Renin-angiotensin system inhibition in conscious sodium-depleted dogs. Effects on systemic and coronary hemodynamics. J Clin Invest 1978; 61: 874-883.
6. Gavras H, Liang C, Brunner HR. Redistribution of regional blood flow after inhibition of the angiotensin converting enzyme. Circ Res 1978; 43 (Suppl 1): S59-S63.
7. Liang C, Gavras H. Renin-angiotensin system inhibition in conscious dogs during acute hypoxemia: effects on systemic hemodynamics, regional blood flows, and tissue metabolism. J Clin Invest 1978; 62: 961-970.
8. Gavras H et al. Angiotensin II inhibition. Treatment of congestive cardiac failure in a high-renin hypertension. JAMA 1977; 238: 880-882.
9. Faxon DP et al. The effect of angiotensin converting enzyme inhibition on coronary blood flow and hemodynamics in patients without coronary artery disease. Int J Cardiol 1982; 2: 251-262.
10. Magrini F et al. Converting-enzyme inhibition and coronary blood flow. Circulation 1987; 75 (Suppl 1): I168-I174.
11. Mettauer B, Rouleau JL, Daly P. The effect of captopril on the coronary circulation and myocardial metabolism of patients with coronary artery disease. Postgrad Med J 1986; 62 (Suppl 1): 54-58.
12. Strozzi C et al. Effects of captopril on the physical work capacity of normotensive patients with stable-effort angina pectoris. Cardiology 1987; 74: 226-228.
13. Strozzi C, Portaluppi F, Cocco G, Urso L. Ergometric evaluation of the effects of enalapril maleate in normo-tensive patients with stable angina. Clin Cardiol 1988;11:246-249.
14. Gasic S, Dudczak R, Korn A, Kleinbloesem C. ACE inhibition with cilazapril improves myocardial perfusion to the ischemic regions during exercise: a pilot study. J Cardiovasc Pharmacol 1990; 15: 227-232.
15. Savage DD et al. Echocardiographic assessment of cardiac anatomy and function in hypertensive subjects. Circulation 1979; 59: 623-632.
16. Pauletto P et al. Ventricular myosin and creatine-kin-ase isoenzymes in hypertensive rats treated with cap-topril. Hypertension 1989; 14: 556-562.
17. Rogers TB, Gaa ST, Allen IS. Identification and characterization of functional angiotensin II receptors on cultured heart myocytes. J Pharmacol Exp Ther 1986; 236: 438-444.
18. Allen IS et al. Angiotensin II increases spontaneous contractile frequency and stimulates calcium current in cultured neonatal rat heart myocytes: insights into the underlying biochemical mechanisms. Circ Res 1988; 62: 524-534.
19. Dostal DE, Baker KM. Evidence for a role of an intracardiac renin-angiotensin system in the normal and failing heart. Trends Cardiovasc Med 1993; 3: 67-74.
20. Dostal DE, Baker KM. Biochemistry, molecular biology, and potential roles of the cardiac renin-angiotensin system. In: Dhalla NS, Beamish RE, Takeda N, Nagano M (eds). The Failing Heart. Lippin-cott-Raven: Philadephia, 1995, pp 275-294.
21. Yu C, Tsai M, Stacey DW. Cellular ras activity and phospholipid metabolism. Cell 1988; 52: 63-71.
22. Knauss TC, Jaffer FE, Abboud HE. Phosphatidic acid modulates DNA synthesis, phospholipase C, and platelet-derived growth factor mRNAs in cultured mesan-gial cells. Role of protein kinase C. J Biol Chem 1990; 265: 14457-14463.
23. Moolenaar WH et al. Growth factor-like action of phos-phatidic acid. Nature 1986; 323: 171-173.
24. Nagano M et al. Converting enzyme inhibitors regressed cardiac hypertrophy and reduced tissue angiotensin II in spontaneously hypertensive rats. J Hypertens 1991; 9: 595-599.
25. Malik KU, Nasjletti A. Facilitation of adrenergic transmission by locally generated angiotensin II in rat mesenteric arteries. Circ Res 1976; 38: 26-30.
26. Newling RP, Fletcher PJ, Contis M, Shaw J. Noradrenaline and cardiac hypertrophy in the rat: changes in morphology, blood pressure and ventricular performance. J Hypertens 1989; 7: 561-567.
27. Campbell DJ. Circulating and tissue angiotensin systems. J Clin Invest 1987; 79: 1-6.
28. Laragh JH. Extrarenal tissue prorenin systems do exist: are intrinsic vascular and cardiac tissue renins fact or fancy? Am J Hypertens 1989; 2: 262-265.
29. Goodfriend TL, Elliott ME, Catt KJ. Angiotensin receptors and their antagonists. N Engl J Med 1996; 334: 1649-1654.
30. Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW. Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141-1148.
31. Ames BN, Shigenaga MK, Hagen TM. Oxidants, antioxidants, and the degenerative disease of aging. Proc Natl Acad Sci USA 1993; 90: 7915-7922.
32. McAlpine HM, Cobbe SM. Neuroendocrine changes in acute myocardial infarction. Am J Med 1988; 84 (Suppl 3A): 61-66.
33. Rouleau JL et al. Activation of neurohumoral systems following acute myocardial infarction. Am J Cardiol 1991; 68: 80D-86D.
34. Braunwald E, Kloner RA. Myocardial reperfusion: a double-edged sword? J Clin Invest 1985; 76: 1713-1719.
35. Li K, Chen X. Protective effects of captopril and enala-pril on myocardial ischemia and reperfusion damage of rat. J Mol Cell Cardiol 1987; 19: 909-915.
36. Tio RA et al. The effects of oral pretreatment with zofenopril, an angiotensin-converting enzyme inhibitor, on early reperfusion and subsequent electrophysio-logic stability in the pig. Cardiovasc Drugs Ther 1990; 4: 695-703.
37. Frei B. Reactive oxygen species and antioxidant vitamin: mechanisms of action. Am J Med 1994; 97 (Suppl 3A): S5-S13.
38. Keaney JF, Frei B. Antioxidant protection of low-den-sity lipoprotein and its role in the prevention of atherosclerotic vascular disease. In: Frei B (ed). Natural Antioxidants in Human Health and Disease. Academic Press: Orlando, 1994, pp 303-351.
39. Keidar S et al. Low density lipoprotein isolated from patients with essential hypertension exhibits increased propensity for oxidation and enhanced uptake by macrophages: a possible role for angiotensin II. Atherosclerosis 1994; 107: 71-84.
40. Brunner HR et al. Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 1972; 286: 441-449.
41. Alderman MH et al. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991; 324: 1098-1104.
42. MacMahon SW, Cutler JA, Furberg CD, Payne GH. The effects of drug treatment for hypertension on morbidity and mortality from cardiovascolar disease: a review of randomized controlled trials. Prog Cardiovasc Dis 1986; 29 (Suppl 1): S99-S118.
43. Chobanian AV, Haudenschild CC, Nickerson C, Drago R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1990; 15: 327-331.
44. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
45. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685-691.
46. Yusuf S et al. Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992; 340: 1173-1178.
47. Sprengers ED, Kluft C. Plasminogen activator inhibitors. Blood 1987; 69: 381-387.
48. Ridker PM. An epidemiologic assessment of thrombotic risk factors for cardiovascular disease. Curr Opin Lipidol 1992; 3: 285-290.
49. Hamsten A et al. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 1987; 2: 3-9.
50. Olson JA Jr et al. Angiotensin II induces secretion of plasminogen activator inhibitor I and a tissue metallo-protease inhibitor-related protein from rat brain astrocytes. Neurobiology 1991; 88: 1928-1932.
51. Ridker PM et al. Stimulation of plasminogen activator inhibitor in vivo by infusion of angiotensin II. Evidence of a potential interaction between the renin-angiotensin system and fibrinolytic function. Circulation 1993; 87: 1969-1973.
52. Saito K, Gutkind JS, Saavedra JM. Angiotensin II binding sites in the conduction system of rat hearts. Am J Physiol 1987; 253: H1618-H1622.
53. Kass RS, Blair ML. Effects of angiotensin II on membrane current in cardiac Purkinje fibers. J Mol Cell Cardiol 1981; 13: 797-809.
54. de Mello WC. Is an intracellular renin-angiotensin system involved in control of cell communication in heart? J Cardiovasc Pharmacol 1994; 23: 640-646.
55. de Mello WC, Crespo MJ. Cardiac refractoriness in rats is reduced by angiotensin II. J Cardiovasc Pharmacol 1995; 25: 51-56.
56. Rajagopalan S et al. Role for endothelin-1 in angiotensin II-mediated hypertension. Hypertension 1997; 30: 29-34.
57. Starke K. Action of angiotensin on uptake, release, and metabolism of 14C-noradrenaline by isolated rabbit hearts. Eur J Pharmacol 1971; 14: 112-123.
58. Aiken JW, Reit E. Stimulation of the cat stellate ganglion by angiotensin. J Pharmacol Exp Ther 1968; 159: 107-114.
59. Lee WB, Ismay MJ, Lumbers ER. Mechanisms by which angiotensin affects the heart rate of the conscious sheep. Circ Res 1980; 47: 286-292.
60. Ponikowski P et al. Heart rhythms, ventricular arrhythmias, and death in chronic heart failure. J Cardiac Failure 1996; 2: 177-183.
61. de Mello WC, Crespo MJ, Altieri PI. Enalapril increases cardiac refractoriness. J Cardiovasc Pharmacol 1992; 20: 820-825.
62. Kingma JH et al. Effects of intravenous captopril on inducible sustained ventricular tachycardia. Postgrad Med 1986; 62: 159-163.
63. Wesseling H et al. Cardiac arrhythmias-a new indication for angiotensin-converting enzyme inhibitors? J Hum Hypertens 1989; 3 (Suppl 1): 89-95.
64. van Gilst WH, de Graeff PA, Wesseling H, de Langen CD. Reduction of reperfusion arrhythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors: a comparison of captopril, enala-pril, and HOE 498. J Cardiovasc Pharmacol 1986; 8: 722-728.
65. Sharma D, Buyse M, Pitt B, Rucinska EJ. Meta-analysis of observed mortality data from all-controlled, doubleblind, multiple-dose studies of losartan in heart failure. Am J Cardiol 2000; 85: 187-192.
66. Elliott WJ. Therapeutic trials comparing angiotensin converting enzyme inhibitors and angiotensin II receptor blockers. Curr Hypertens Rep 2000; 2: 402-411.
67. Kranzhofer R et al. Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 1999; 19: 1623-1629.
68. Han Y, Runge MS, Brasier AR. Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kappa B transcription factors. Circ Res 1999; 84: 695-703.